In the past few years, numerous technologies have been developed that utilize AI to diagnose eye diseases like Glaucoma and Macular Degeneration. These technologies generally work by analyzing the data from an optic nerve examination, optical coherence tomography or visual field examination. However, one fatal flaw many of these tests share is that they cannot be used on individuals suffering from myopia (nearsightedness).
Samsung's latest patent application (U.S. Pub. No. 20200187775) looks to solve this flaw. The application teaches of a method using AI to diagnose eye diseases in patients also suffering from nearsightedness. As with many AI-based diagnostic methods, the software utilizes a library of data from previously diagnosed patients to perform its analysis. In Samsung's case, they have built a library of data from people who suffer from eye diseases both with and without nearsightedness. Using deep learning, the software is able to overlook the effect being nearsighted has on the measurements, and accurately diagnose eye diseases.
While it isn't exactly clear what Samsung has planned for this new technology, it is the company's second patent in the AI-Ocular field in the past year. Other competitors in the field include technology powerhouses such as IBM and Microsoft.
Stay up-to-date with the most recent AI/Biotech diagnostic patent activity and related news with the Magic Number® AI Biotech/Diagnostics Patent Forecast®.
